In brief · RUO
- After a stroke or brain injury, damage comes in two waves: the direct injury, and a second wave of over-excitation and inflammation. Much peptide research targets that second wave.
- The striking 2025 headline: CAQK, a tiny peptide, cut brain-injury size by ~50% in mice and pigs (preclinical; human study planned).
- At the same time failed a large stroke trial with the peptide nerinetide — a sharp reminder that animal research does not simply translate to humans.
- Semax (catalog-linkable) is studied in this field, but the evidence is largely preclinical and regional.
- This article discusses research. Peplife supplies these compounds strictly Research Use Only — no medical or usage advice.
What is this about?
In a stroke (a blocked or burst blood vessel in the brain) or a traumatic brain injury (TBI, e.g., from a blow), part of the tissue dies immediately. But the damage doesn't stop there: a second wave follows in which cells become over-excited, inflammation flares, and more tissue is lost. Much peptide research targets that second wave — hoping to interrupt the "domino effect." Importantly, this is largely preclinical research, and the path to humans is notoriously hard.
Under the hood: where do peptides act?
Damage after brain injury follows recognizable steps; peptides try to intervene at different points:
1. Dampening excitotoxicity. After injury a flood of glutamate over-excites nearby cells until they die. Some peptides (like nerinetide) try to block this cascade.
2. Steering inflammation. Immune cells clear debris but can also add damage; peptides try to shift the balance toward repair.
3. Targeted "homing." Some peptides (like CAQK) bind specifically to a protein that rises after injury (tenascin-C), so a payload arrives right at the damaged spot.
4. Neurotrophic support. Peptides that raise growth factors such as BDNF (like Semax) try to help surviving neurons recover and form connections.
What is excitotoxicity? After brain injury, a flood of the messenger glutamate is released. It over-excites nearby cells so strongly that they die — like a speaker blown out by too much volume. Many neuroprotective peptides try to temper exactly this process.
The 2025 breakthrough headline: CAQK
CAQK is a tetrapeptide — a chain of just four building blocks. It "homes" to injured brain tissue by binding tenascin-C, a protein that spikes after injury. In a December 2025 study, CAQK given via the bloodstream cut injury size by about 50% in both mice and pigs, with less cell death and inflammation and better recovery of movement and memory — with no signs of toxicity. That the effect also appeared in pigs (whose brain more closely resembles a human's) makes it notable. The team plans to seek FDA approval for a first human study (EMBO Molecular Medicine, Dec 2025; ScienceDaily).
Study type: preclinical (animal). No human data yet — a human study is only planned. CAQK is a research reagent, not a catalog item.
Why translation is so hard: nerinetide
That hope is tempered by a sober lesson. Nerinetide is a peptide that blocks the protein PSD-95 and thereby aims to interrupt the “excitotoxic” cascade — promising for years in animal research. But in the large ESCAPE-NEXT-trial (2025) did not improve recovery after a stroke compared with placebo (The Lancet00194-1/abstract)). A meta-analysis of three randomised trials (1,394 patients) confirmed: no significant effect (Neuroradiology 2025). Promising animal research therefore does not automatically mean results in humans — a principle to keep in mind with every peptide claim.
Study type: phase 3 RCT + meta-analysis (human). Nerinetide is an investigational drug, not a catalog item.
Semax: catalog-linkable, but evidence with nuance
Semax is a synthetic fragment of the hormone ACTH, developed in Russia. In animal models it raises BDNF — a kind of "fertilizer" protein that helps neurons grow and form connections — and its receptor TrkB in the hippocampus, the memory region (ScienceDirect). There are Russian studies of Semax as an add-on in acute stroke (PubMed), but these are mostly small, regional studies — not large Western trials. Honestly: the evidence is preliminary.
Cerebrolysin and ApoE-mimetics
Cerebrolysin is a mix of small peptides from pig brain tissue, studied to support recovery. A meta-analysis of 14 randomized trials (2025) assessed its safety and effect on neurological recovery after stroke (PubMed); a small pilot looked at speech (aphasia) recovery combined with speech therapy (Stroke/AHA 2024). In addition, ApoE-mimetic peptides (such as CN-105) are studied to limit secondary damage after injury (review, Neurotherapeutics01993-1/fulltext)). And a 2025 review discusses mitochondrial peptides such as humanin in neurodegenerative disease (Molecular Neurobiology).
Overview: approaches and evidence
| Approach | Mechanism | Strongest evidence | Evidence level |
|---|---|---|---|
| CAQK | homes to injury (tenascin-C) | ~50% smaller lesion, mouse + pig (2025) | preclinical; human study planned |
| Nerinetide | blocks excitotoxicity (PSD-95) | ESCAPE-NEXT + meta-analysis | phase 3 RCT — no effect |
| Semax | raises BDNF/TrkB | animal + small regional clinical | preclinical + weak/regional |
| Cerebrolysin | neurotrophic peptide mix | meta-analysis 14 RCTs (2025) | clinical, mixed |
| ApoE-mimetics (CN-105) | limits secondary damage | reviews / early phase | preclinical/early-clinical |
| Humanin | mitochondrial, neuroprotection | neurodegeneration review (2025) | preclinical |
Nuance & limitations (important)
- Strong science ≠ available compound. The best-supported agents here (CAQK, nerinetide, CN-105) are not webshop products; the catalog-linkable agent (Semax) rests on thinner, regional evidence.
- Nerinetide is a warning. Years of promising animal research led to a failed phase 3 — the definitive lesson on animal→human translation.
- CAQK is still animal research. Impressive, but without human data; a human study is only planned.
- "Neuroprotection in a model" ≠ recovery in patients. We name that distinction deliberately.
Related research · RUO
- Knowledge base: Semax research, Cognitive peptides and DSIP research (internal compound/theme pillars).
- RUO research materials: Semax (laboratory research only).
Frequently asked questions
Do peptides repair brain damage?
Research studies whether they influence processes like over-excitation and inflammation. Much is preclinical; it is not a proven treatment.
What is the CAQK breakthrough?
An animal study (2025) in which a small peptide cut brain-injury size by ~50%, also in pigs. No human data yet; a human study is planned.
Why did nerinetide fail?
In large trials it did not improve recovery — an example of how hard it is to translate animal research to humans.
Is Semax proven for stroke?
There are (mostly Russian, small) studies; the evidence is limited and regional.
Does Peplife supply a CoA?
Yes, independently tested with a CoA per batch.
Disclaimer
This article discusses scientific research and is informational only. The compounds mentioned are supplied by Peplife strictly as Research Use Only (RUO) for laboratory research. Nothing here is medical, diagnostic, or dosing advice. Named medicines are cited only to discuss published research.